AlloCure names Kevin Heyeck chief business officer
This article was originally published in Scrip
Executive Summary
AlloCure, a privately held US biotechnology company developing therapies for the treatment of kidney disease, has appointed Kevin Heyeck chief business officer. He has more than 20 years experience in business development and corporate partnering for emerging pharmaceutical companies, having previously served as vice-president of business development at Vitae Pharmaceuticals. Before that, he headed business development for Pharmacopeia.